Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 3/20 | 0.50 |
| ▸ | SRC | P12931 | 15/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 13/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | GLA | P06280 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | LYN | P07948 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2361080 | 0.79 | SRC (0.41) | BTKSRCFGFR1ALDH1A1GLA | |
| SCHEMBL2361093 | 0.77 | BTK (0.49) | BTKSRCFGFR1ALDH1A1GLA | |
| SCHEMBL31532090 | 0.75 | FGFR1 (0.60) | FGFR1ALDH1A1GLAMAPK1HSD17B10 | |
| SCHEMBL24665031 | 0.75 | FGFR1 (0.43) | BTKSRCFGFR1ALDH1A1GLA | |
| SCHEMBL2360516 | 0.72 | SRC (0.48) | SRCFGFR1LYN | |
| SCHEMBL25318819 | 0.68 | ALDH1A1 (0.40) | FGFR1ALDH1A1GLAMAPK1HSD17B10 | |
| SCHEMBL17119577 | 0.67 | BTK (1.00) | BTKSRCLYN | |
| SCHEMBL189249 | 0.66 | ALDH1A1 (0.63) | BTKFGFR1ALDH1A1GLAMAPK1 | |
| SCHEMBL13560809 | 0.65 | KDM4E (0.45) | ALDH1A1GLAHSD17B10MEN1USP2 | |
| SCHEMBL29861345 | 0.64 | WEE1 (0.41) | BTKSRCFGFR1ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2531498-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2016-07-13 | — | — | EP | disclosed |
| EP-2531498-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2016-07-13 | — | — | EP | disclosed |
| US-9181238-B2 | N-(pyridin-2-yl)sulfonamides and compositions thereof as protein kinase inhibitors | NOVARTIS AG (CH) | 2015-11-10 | — | — | US | disclosed |
| US-20130143899-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG | 2013-06-06 | — | — | US | disclosed |
| EP-2531498-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2012-12-12 | — | — | EP | disclosed |
| WO-2011097526-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-08-11 | — | — | WO | disclosed |
| WO-2011097526-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143899-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | RAF1, BRAF, ARAF | BTK 79/4885SRC 107/4885FGFR1 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.